Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer

Pharmacology, Toxicology and Pharmaceutical Science

• Estrogen Receptor 100%
• Estrogen Receptor Positive Breast Cancer 100%
• Trastuzumab 100%
• Protein Tyrosine Kinase Inhibitor 100%
• Receptor 33%
• Breast Cancer 33%
• Western Blot 33%
• Lapatinib 33%
• IC50 33%
• Combination Drug 33%
• Acid Phosphatase 33%
• Caspase 3 33%
• Trastuzumab Emtansine 33%
• Tucatinib 33%
• Neratinib 33%

Biochemistry, Genetics and Molecular Biology

• Estrogen Receptor 100%
• Tyrosine Kinase Inhibitor 50%
• Trastuzumab 50%
• Programmed Cell Death 33%
• Signal Transduction 16%
• IC50 16%
• Western Blot 16%
• Antiproliferative Activity 16%
• Acid Phosphatase 16%
• Caspase 3 16%
• Trastuzumab Emtansine 16%
• Lapatinib 16%
• Neratinib 16%